[1] J. M. Ducoté and C. W. Dewey, “Neurodiagnostic,” In: C. W. Dewey, Ed., A Practical Guide to Canine and Feline Neurology, Blackwell Publishing, Ames, 2003, pp. 99-178.
http://dx.doi.org/10.1111/j.1467-2995.2005.00221.x
[2] P. A. March and W. W. Muir, “Bispectral Analysis of the Electroencephalogram: A Review of Its Development and Use in Anesthesia,” Veterinary Anaesthesia and Analgesia, Vol. 32, No. 5, 2005, pp. 241-255.
[3] H. S. Jang, Y. S. Kwon, M. G. Lee, et al., “The Effect of Tiletamine/Zolazepam (Zoletile) Combination with Xylazine or Medetomidine on Electroencephalograms in Dogs,” The Journal of Veterinary Medical Science, Vol. 66, No. 5, 2004, pp. 501-507.
http://dx.doi.org/10.1292/jvms.66.501
[4] D. Stenberg, “Physiological Role of Alpha 2-Adrenoceptors in the Regulation of Vigilance and Pain: Effect of Medetomidine,” Acta Veterinaria Scandinavica. Supplementum, Vol. 85, 1989, pp. 21-28.
[5] M. D. Lorenz and J. N. Kornegay, “Seizures, Narcolepsy and Cataplexy,” In: M. D. Lorenz and J. N. Kornegay, Eds., Handbook of Veterinary Neurology, 4th Edition, Saunders, St. Louis, 2004, pp. 323-339.
[6] R. W. Redding, R. B. Prynn and J. L. Wagner, “Clinical Use of the Electroencephalogram in Canine Encephalitis,” American Veterinary Medical Association, Vol. 148, 1966, pp. 141-149.
[7] N. Lemo, D. Vnuk, B. Radisic, et al., “Determination of the Toxic Dose of Lidocaine in Dogs and Its Corresponding Serum Concentration,” Veterinary Record, Vol. 160, No. 11, 2007, pp. 374-375.
http://dx.doi.org/10.1136/vr.160.11.374
[8] W. B. Pickworth, L. G. Sharpe and V. N. Gupta, “Morphine-Like Effects of Clonidine on the EEG, Slow Wave Sleep and Behavior in the Dog,” European Journal of Pharmacology, Vol. 81, No. 4, 1982, pp. 551-557.
http://dx.doi.org/10.1016/0014-2999(82)90344-2
[9] K. Itamoto, Y. Taura, N. Wada, et al., “Effect of Medetomidine on Electroencephalography and Use of a Quantitative Electroencephalograph for Evaluating Sedation Levels in Dogs,” Journal of Veterinary Medicine Series A, Vol. 48, No. 9, 2001, pp. 525-535.
http://dx.doi.org/10.1046/j.1439-0442.2001.00381.x
[10] R. Virtanen, “Pharmacological Profiles of Medetomidine and Its Antagonist, Atipamezole,” Acta Veterinaria Scandinavica, Vol. 85, 1989, pp. 29-37.
[11] A. Pitkänen, S. Narkilahti, Z. Bezvenyuk, et al., “Atipamezole, an Alpha(2)-Adrenoceptor Antagonist, Has Disease Modifying Effects on Epileptogenesis in Rats,” Epilepsy Research, Vol. 61, No. 1-3, 2004, pp. 119-140.
http://dx.doi.org/10.1016/j.eplepsyres.2004.07.005
[12] M. D. Sinclair, “A Review of the Physiological Effects of Alpha2-Agonists Related to the Clinical Use of Medetomidine in Small Animal Practice,” The Canadian Veterinary Journal, Vol. 44, No. 11, 2003, pp. 885-897.
[13] C. E. Short, “Alpha 2 Agents in Animals,” In: C. E. Short, Ed., Alpha 2 Agents in Animals Sedation, Analgesia and Anaesthesia, Vol. 1, Veterinary Practice Publishing, Santa Barbara, 1992, pp. 1-55.
[14] O. Vainio and T. Vaha-Vahe, “Reversal of Medetomidine Sedation by Atipamezole in Dogs,” Journal of Veterinary Pharmacology and Therapeutics, Vol. 13, 1990, pp. 15-22.
http://dx.doi.org/10.1111/j.1365-2885.1990.tb00742.x